Toggle

A drug, TLN-121, alone and in combination with TLN-254, to treat non-Hodgkin lymphoma (NHL) that has come back (relapsed) or not gotten better with treatment (refractory)

Print

18 and older

Phase 1

4 Locations

NCT07082803

Clinical Trial Goal


To find out:
  • The highest dose of TLN-121 that's safe to give
  • If TLN-121, alone and in combination with TLN-254, is safe and works well to treat NHL that has relapsed or is refractory

You may be able to join this trial if you:


  • Are 18 years old or older
  • Have NHL that has relapsed or is refractory. Some examples include:
    • Diffuse large B-cell lymphoma (DLBCL)
    • Follicular lymphoma
    • Peripheral T-cell lymphoma (PTCL)
  • Do not have lymphoma in your brain or spinal cord
  • Have not had an allogeneic (cells from a donor) blood or marrow transplant (BMT) in the last 3 months
  • Have not had an autologous (your own cells) BMT in the last 2 months
  • Agree to have other standard tests done to see if you can be in the clinical trial 

Trial Details


TLN-121 is a drug that doctors believe will find and attack cancer cells. 
TLN-254 is a drug that doctors believe will find and attack cancer cells. 

You’ll get:
  • TLN-121 – The dose you'll get depends on when you start the trial and how safe it has been
  • TLN-254 – The dose you'll get depends on when you start the trial and how safe it has been

You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 2 years.

The Food and Drug Administration (FDA) has not yet approved TLN-121 or TLN-254. 

Contacts


Treeline Clinical Operations, 857-228-0050, clinicaloperations@treeline.bio

Locations


The START Center for Cancer Care - MidwestRECRUITING

Grand Rapids, Michigan
Andrew Sochacki, 616-389-1800, andrew.sochacki@startmidwest.com

Washington University School of MedicineRECRUITING

St Louis, Missouri
Amalia Dubois, 314-273-1486, amalia@wustl.edu

SCRI Oncology PartnersRECRUITING

Nashville, Tennessee
Principal Investigator, (615) 339-0516, Sydney.Fitzgerald@scri.com

The University of Texas MD Anderson Cancer CenterRECRUITING

Houston, Texas
Dai Chihara, Dr., 713-792-2860, DChihara@mdanderson.org

ClinicalTrials.gov record


NCT07082803. First posted on Jul 24

Call center employee on the phone offering help to a caller

Questions? Contact our Clinical Trials Navigator

1-888-814-8610
contact@ctsearchsupport.org